

News Release

Lonza Collaborates with Takeda to Bring Cancer Treatment to Patients

- European Commission approved ALUNBRIG® (brigatinib), once-daily tablet for adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
- The Lonza team in Tampa, FL (USA) collaborated with Takeda to provide support from early drug product development studies through commercial supply to help bring this new cancer treatment to patients.
- ALUNBRIG is already approved by the U.S. Food and Drug Administration (FDA) for use in this setting in the United States.

Basel, Switzerland, 11 January 2019 – Lonza today announced another major milestone in its multiproduct partnership with Takeda. Takeda Pharmaceutical Company Limited announced in November 2018 that the European Commission (EC) granted marketing authorization for ALUNBRIG (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NLSC) previously treated with crizotinib.

Scientists at Lonza Pharma & Biotech's integrated product development and manufacturing facility in Tampa, FL (USA) have collaborated with Takeda on this cancer treatment from product development through commercial approval. The Lonza team has provided support from the original IND and IMPD approvals to formulation, as well as for method and process development for multiple strengths of ALUNBRIG. Lonza's Tampa team also produced clinical material for Phase 1, 2 and 3 studies and now holds EU GMP certificates for manufacturing, packaging and QC testing of commercial ALUNBRIG.

"As Takeda's partner for the development and manufacture of ALUNBRIG, we are playing a role in helping to bring this oncology drug to the patients who need it," said Christian Dowdeswell, Lonza's Dosage Forms & Delivery Solutions Business Unit Head. "This approval is an important milestone; and we expect to continue the exceptionally collaborative and highly productive relationship that our two companies have enjoyed over the last six years."

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com.

Lonza Contact Details

Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com



Pharma&Biotech

Lonza Ltd
Muenchensteinerstrasse 38
CH-4002 Basel
Switzerland
+41 61 316 81 11
+41 61 316 91 11
media@lonza.com

Lonza

Constance Ward, Head External Communications

Lonza Group Ltd
Tel +41 61 316 8840
constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

ALUNBRIG® is a registered trademark of Takeda Pharmaceutical Company Limited.